Search research articles
Contact Us
Filters
Showing results (131-140 of 212) with videos related to
Page
of 22
Sort By:
The Oncologist
|
June 12, 2016
Prognosis of Mucosal, Uveal, Acral, Nonacral Cutaneous, and Unknown Primary Melanoma From the Time of First Metastasis
Deborah Kuk, Alexander N Shoushtari, Christopher A Barker, et al.
Cancer Cell
|
June 13, 2018
Non-conventional Inhibitory CD4<sup>+</sup>Foxp3<sup>-</sup>PD-1<sup>hi</sup> T Cells as a Biomarker of Immune Checkpoint Blockade Activity
Roberta Zappasodi, Sadna Budhu, Matthew D Hellmann, et al.
Cell Reports
|
April 12, 2025
Quantitatively defined stromal B cell aggregates are associated with response to checkpoint inhibitors in unresectable melanoma
James W Smithy, Xiyu Peng, Fiona D Ehrich, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 10, 2019
Treatment-Free Survival: A Novel Outcome Measure of the Effects of Immune Checkpoint Inhibition-A Pooled Analysis of Patients With Advanced Melanoma
Meredith M Regan, Lillian Werner, Sumati Rao, et al.
JAMA Oncology
|
January 20, 2022
Early Readout on Overall Survival of Patients With Melanoma Treated With Immunotherapy Using a Novel Imaging Analysis
Laurent Dercle, Binsheng Zhao, Mithat Gönen, et al.
Ophthalmology
|
November 12, 2019
Intravitreous Cutaneous Metastatic Melanoma in the Era of Checkpoint Inhibition: Unmasking and Masquerading
Jasmine H Francis, Duncan Berry, David H Abramson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 29, 2016
Reaffirming and Clarifying the American Society of Clinical Oncology's Policy Statement on the Critical Role of Phase I Trials in Cancer Research and Treatment
Jeffrey S Weber, Laura A Levit, Peter C Adamson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 3, 2016
An Open-Label, Dose-Escalation Phase I Study of Anti-TYRP1 Monoclonal Antibody IMC-20D7S for Patients with Relapsed or Refractory Melanoma
Danny N Khalil, Michael A Postow, Nageatte Ibrahim, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 20, 2021
Adaptive Dosing of Nivolumab + Ipilimumab Immunotherapy Based Upon Early, Interim Radiographic Assessment in Advanced Melanoma (The ADAPT-IT Study)
Michael A Postow, Debra A Goldman, Alexander N Shoushtari, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 13, 2016
Increases in Absolute Lymphocytes and Circulating CD4+ and CD8+ T Cells Are Associated with Positive Clinical Outcome of Melanoma Patients Treated with Ipilimumab
Alexander Martens, Kilian Wistuba-Hamprecht, Jianda Yuan, et al.
Page
of 22
Search research articles
Search
Showing results (131-140 of 212) with videos related to
Sort By:
Page
of 22
The Oncologist
|
June 12, 2016
Prognosis of Mucosal, Uveal, Acral, Nonacral Cutaneous, and Unknown Primary Melanoma From the Time of First Metastasis
Deborah Kuk, Alexander N Shoushtari, Christopher A Barker, et al.
Cancer Cell
|
June 13, 2018
Non-conventional Inhibitory CD4<sup>+</sup>Foxp3<sup>-</sup>PD-1<sup>hi</sup> T Cells as a Biomarker of Immune Checkpoint Blockade Activity
Roberta Zappasodi, Sadna Budhu, Matthew D Hellmann, et al.
Cell Reports
|
April 12, 2025
Quantitatively defined stromal B cell aggregates are associated with response to checkpoint inhibitors in unresectable melanoma
James W Smithy, Xiyu Peng, Fiona D Ehrich, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 10, 2019
Treatment-Free Survival: A Novel Outcome Measure of the Effects of Immune Checkpoint Inhibition-A Pooled Analysis of Patients With Advanced Melanoma
Meredith M Regan, Lillian Werner, Sumati Rao, et al.
JAMA Oncology
|
January 20, 2022
Early Readout on Overall Survival of Patients With Melanoma Treated With Immunotherapy Using a Novel Imaging Analysis
Laurent Dercle, Binsheng Zhao, Mithat Gönen, et al.
Ophthalmology
|
November 12, 2019
Intravitreous Cutaneous Metastatic Melanoma in the Era of Checkpoint Inhibition: Unmasking and Masquerading
Jasmine H Francis, Duncan Berry, David H Abramson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 29, 2016
Reaffirming and Clarifying the American Society of Clinical Oncology's Policy Statement on the Critical Role of Phase I Trials in Cancer Research and Treatment
Jeffrey S Weber, Laura A Levit, Peter C Adamson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 3, 2016
An Open-Label, Dose-Escalation Phase I Study of Anti-TYRP1 Monoclonal Antibody IMC-20D7S for Patients with Relapsed or Refractory Melanoma
Danny N Khalil, Michael A Postow, Nageatte Ibrahim, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 20, 2021
Adaptive Dosing of Nivolumab + Ipilimumab Immunotherapy Based Upon Early, Interim Radiographic Assessment in Advanced Melanoma (The ADAPT-IT Study)
Michael A Postow, Debra A Goldman, Alexander N Shoushtari, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 13, 2016
Increases in Absolute Lymphocytes and Circulating CD4+ and CD8+ T Cells Are Associated with Positive Clinical Outcome of Melanoma Patients Treated with Ipilimumab
Alexander Martens, Kilian Wistuba-Hamprecht, Jianda Yuan, et al.
Page
of 22